You are here » Home » Companies » Company Overview » ACE Laboratories Ltd

ACE Laboratories Ltd.

BSE: 526077 Sector: Health care
NSE: ACELAB ISIN Code: N.A.
BSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN
PREVIOUS CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr)
Buy Price
Buy Qty
Sell Price
Sell Qty
OPEN
CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr)
Buy Price
Buy Qty
Sell Price
Sell Qty

ACE Laboratories Ltd. (ACELAB) - Chairman Speech

Company chairman speech

ACE LABORATORIES LIMITED CHAIRMAN REPORT SHAPING THE EMPIRES OF THE FUTURE The empires of the future, we know, are built by those who have the will and foresight to shape it now. With synergy, expansion & consolidation forming the core of our futuristic reality. We have in a decade of existence, not only pursued the process of making profits and building goodwill but constantly worked towards building a strong foundation for the future. A move called" Shape your Future" that was launched three years back with a Rs.60 crores expansion & Diversification programme. Joint Ventures in Nepal, Uzbekistan and Mauritius, technology transfer from China, Korea, Nil, ICGEB Dept. of Technology ( Govt. of India) & NRDC, commissioning of Bulk Drugs & intermediate/ Chemical project, injectable unit, R & D centre and a comprehensive programme for expansion of capacities for formulation, a Venture into new drug delivery system (targetted) in Parenterals- these are some of the pillars of our future empires . Each a sure-fire success., will translate into gainsome business opportunities besides of course making a solid & strong foothold for ACE. We are not overtly proud or complacent for what we have achieved , rather we believe that Shaping the future is a process that calls for continuous redirection & redefinition of goals and fine tuning with passionate dedication and discernment. In this endeavour, we have established facilities for Cefuroxime Axetil and also maintain to have a firm footing on drug intermediates i.e. EMME and TEOF- used for production of Quinolone, Chloroquine Phosphate, Norfloxacin etc. In short this breakthrough will give a major strategic boost to ACE by streamlining operations from the very basis stage. ACE is growing from strength to strength-rapidly marching into the next millennium. With invaluable support from our esteemed shareholders and other participants, we are virtually guaranteed a great future. Ajit Chand Srimal

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard